Criteria for Concerning Ventricular Tachycardia Requiring Urgent Treatment
Any wide-QRS tachycardia (QRS ≥120 ms, rate >100 bpm) should be presumed to be VT if the diagnosis is unclear, and immediate treatment is indicated when hemodynamic compromise is present. 1
Hemodynamic Instability Criteria (Immediate Cardioversion Required)
Direct current cardioversion is mandatory when ANY of these adverse signs are present: 1, 2, 3
- Systolic blood pressure ≤90 mm Hg
- Altered mental status or loss of consciousness
- Chest pain/ongoing ischemia
- Heart failure symptoms
- Heart rate ≥150 bpm (particularly concerning threshold)
- Absence of pulse (treat as VF protocol)
These criteria define hemodynamically unstable VT where electrical cardioversion takes absolute priority over pharmacologic therapy. The 2025 AHA guidelines emphasize prompt synchronized cardioversion for unstable patients, with sedation if the patient is conscious 4.
Additional High-Risk Features Requiring Urgent Intervention
Polymorphic VT
- Always concerning - should be treated similarly to VF with unsynchronized 200J shock 5, 3
- Suggests acute ischemia, electrolyte abnormalities, or inherited channelopathies
- Requires immediate beta-blocker therapy if recurrent, especially when ischemia suspected 1
Electrical Storm
≥3 episodes of VT/VF within 24 hours - this defines electrical storm and mandates: 6
- Non-selective beta-blocker (propranolol preferred over metoprolol)
- IV amiodarone
- Consider sedation/anesthesia
- Early involvement of electrophysiology specialist
- Aggressive heart failure management if present
Sustained VT (>30 seconds or requiring termination <30 seconds)
Even if hemodynamically tolerated, sustained monomorphic VT warrants timely termination because: 1
- Risk of deterioration to hemodynamic instability
- Risk of progression to polymorphic VT or VF
- Metabolic and hemodynamic decompensation with prolonged episodes 7
Rate-Based Thresholds
The 150 bpm threshold is critical: 2, 5
- Rate >150 bpm: Immediate cardioversion generally indicated even if initially stable
- Rate <150 bpm: Immediate cardioversion generally not needed; brief medication trial reasonable if stable
Rapid polymorphic VT should be managed with unsynchronized 200J shock, while monomorphic VT >150 bpm can be treated with 100J synchronized cardioversion. 5
Context-Specific Concerns
Acute Coronary Syndrome
VT occurring within 48 hours of ACS onset carries increased hospital mortality 1. Priority interventions:
- Correct hypokalemia and ongoing ischemia immediately
- Consider lidocaine specifically for ischemia-related VT 1
Structural Heart Disease
VT in the presence of structural heart disease (prior MI, cardiomyopathy, reduced LVEF) is inherently higher risk than idiopathic VT 8, 9. These patients require:
- Lower threshold for cardioversion
- ICD consideration for secondary prevention
- Aggressive underlying disease management
Post-MI Timing
- VT/VF occurring >48 hours post-MI deserves careful evaluation including possible EP study, as this suggests mature arrhythmic substrate rather than acute ischemia 5
- Monomorphic VT at rates <170 bpm post-MI is unusual and suggests chronic substrate 5
Common Pitfalls to Avoid
Never use calcium channel blockers (verapamil, diltiazem) for wide-QRS tachycardia of unknown origin - this is Class III (harmful), especially with myocardial dysfunction 1
Do not delay cardioversion for medication trials in unstable patients - electrical therapy is first-line 1, 3, 4
Adenosine may precipitate VF in true VT - use cautiously only in stable, regular, monomorphic wide-complex tachycardia where SVT with aberrancy is genuinely possible 4
Beware of assuming SVT with aberrancy - in patients with structural heart disease, wide-complex tachycardia is VT until proven otherwise 1
Stable VT Management Algorithm
For hemodynamically stable sustained monomorphic VT: 1, 4
First-line options:
- Electrical cardioversion (most efficacious) 10
- IV procainamide (Class IIa, most appropriate for early termination) - 20-50 mg/min until arrhythmia suppressed, hypotension, or QRS widens >50%
Second-line:
- IV amiodarone (reasonable for refractory or recurrent VT despite procainamide)
- IV lidocaine (only for ischemia-related VT, Class IIb)
The 2006 ACC/AHA/ESC guidelines specifically note that IV amiodarone is not ideal for early conversion of stable monomorphic VT, while procainamide is more appropriate for early slowing and termination 1. This contrasts with the common practice of reaching for amiodarone first.